<DOC>
	<DOCNO>NCT01394003</DOCNO>
	<brief_summary>The main purpose trial determine recommend Phase 2 dose LY2584702 may safely administer patient advanced/metastatic cancer .</brief_summary>
	<brief_title>A Study LY2584702 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Have histological cytological evidence diagnosis advance and/or metastatic cancer ( solid tumor ) refractory standard therapy and/or therapy know provide clinical benefit , standard therapy exists Have presence disease amenable efficacy assessment define Response Evaluation Criteria Solid Tumors . Patients advance nonmeasurable disease elevation validate tumor marker may eligible , discuss agree upon investigator sponsor Patients enter Part C study must tumor safely amenable 2 biopsy ( one pretreatment one ontreatment biopsy tumor ) . Patients Part C study must agree biopsy procedure time consent Have adequate hematologic , renal , hepatic organ function Have performance status less equal 2 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous therapy cancer , include chemotherapy , radiotherapy , cancerrelated hormonal therapy ( exception continue gonadotropic release hormone ( GnRH ) agonist therapy patient prostate cancer , antiestrogen therapy [ example , aromatase inhibitor ] patient breast cancer ) , investigational therapy least 3 week ( 6 week mitomycinC nitrosoureas ) prior study enrollment recover acute effect therapy Are reliable willing available duration study willing follow study procedure Males female reproductive potential must agree use medically approve contraceptive precaution trial 3 month follow last dose study drug Females child bear potential must negative serum pregnancy test less equal 7 day prior first dose study drug Have estimate life expectancy great equal 12 week Are able swallow capsule Have receive treatment within 3 week initial dose study drug drug receive regulatory approval indication Have 1 serious preexist medical condition , opinion investigator , would preclude participation study . Have symptomatic central nervous system ( CNS ) malignancy metastasis . Patients treat CNS metastasis eligible provided disease radiographically stable , asymptomatic , currently receive corticosteroid and/or anticonvulsant . Screening asymptomatic patient without history CNS metastasis require Have hematologic malignancy , lymphoma Females pregnant lactate Have second primary malignancy , judgment investigator sponsor , may affect interpretation result Have bleed diathesis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Advanced cancer</keyword>
</DOC>